

Application No. 10/639,948
Confirmation No. 6989


Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount of a combination of a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, and a therapeutic cardiovascular compound selected from the group consisting of an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, a calcium channel blocker, a β -adrenergic receptor antagonist, a vasodilator, a diuretic, an α -adrenergic receptor antagonist, an antioxidant, and a mixture thereof,

wherein the 3-acylated pyridoxal analogue is a compound of the formula




wherein

R_1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R_2 is a secondary amino group.

Claim 2 (original): A method according to claim 1, wherein the 3-acylated pyridoxal analogue is a compound of the formula


Application No. 10/639,948
Confirmation No. 6989



wherein

R₁ is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group.

Claim 3 (original): A method according to claim 1, wherein the 3-acylated pyridoxal analogue is a compound of the formula



wherein

R₁ is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

R₂ is a secondary amino group.

Claim 4 (original): A method according to claim 1, wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, lisinopril, benzazpril, fosinopril, quinapril, ramipril, spirapril, imidapril, or moexipril.

Claim 5 (original): A method according to claim 1, wherein the angiotensin II receptor antagonist is losartan or valsartan.

Claim 6 (original): A method according to claim 1, wherein the calcium channel blocker is verapamil, diltiazem, nicardipine, nifedipine, amlodipine, felodipine, nimodipine, or bepridil.

Application No. 10/639,948
Confirmation No. 6989

Claim 7 (original): A method according to claim 1, wherein the compound is administered enterally or parenterally and the therapeutic cardiovascular compound is administered enterally or parenterally.

Claim 8 (original): A method according to claim 1, wherein the compound and the therapeutic cardiovascular compound are administered in a single dosage form.

Claim 9 (previously presented): A method according to claim 1, wherein the β -adrenergic receptor antagonist is atenolol, propranolol, timolol or metoprolol.

Claim 10 (previously presented): A method according to claim 1, wherein the diuretic is furosemide, diuril, amiloride or hydrodiuril.

Claim 11 (previously presented): A method according to claim 1, wherein the α -adrenergic receptor antagonist is prazosin, doxazocin or labetalol.

Claim 12 (previously presented): A method according to claim 1, wherein the antioxidant is vitamin E, vitamin C or an isoflavone.